Optimizing adenovirus vector-based vaccine production

Arriving at the University of Oxford in late 2019, postdoctoral researcher Carina Joe hoped to apply her skills in biologics manufacturing to viral vector vaccines, a new area for her. Within months, she was at the center of efforts to produce the Oxford/AstraZeneca COVID-19 vaccine, one of the first and most widely used COVID-19 vaccines. Charlotte Barker, Editor, Vaccine Insights, caught up with Carina Joe (pictured), now a Senior Scientist, to find out more about her role in scaling up the adenovirus-vectored vaccine, and her plans for the future.

Please enter your email to access content Read now